Skip to main content

Invokana (Canagliflozin) & Renal Cell Carcinoma

Basic Details
Status
Ongoing
Last Updated
Monday, November 9, 2026
Original Posting Date
Health Outcome(s)
renal cell carcinoma
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
Yes
Analytic Code Link(s) (1)
Risk of Renal Cell Carcinoma Associated with Canagliflozin Versus Sitagliptin in Type 2 Diabetes: A Clone-Censor-Weight Cohort Study
Result(s) (2)
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis Risk of Renal Cell Carcinoma Associated with Canagliflozin Versus Sitagliptin in Type 2 Diabetes: A Clone-Censor-Weight Cohort Study
Regulatory Link(s) (1)
FDA Approval Package Materials
Related Publication(s) and/or Presentation(s) (3)
Presentation: Use of Glucagon-Like Peptide-1 Receptor Agonists in the U.S. Food and Drug Administration’s Sentinel System Presentation: Combining Treatment Propensity Scores and Clone-Censor-Weighting to Evaluate Treatment Duration in Active Comparator Studies Presentation: Risk of Renal Cell Carcinoma Following At Least 180 Days of Exposure to Canagliflozin in U.S. Patients with Type 2 Diabetes Mellitus